APA

Engmann L. L., Maslow B. S., Kaye L. A., Griffin D. W., DiLuigi A. J., Schmidt D. W., Grow D. R., Nulsen J. C. & Benadiva C. A. (20190215). Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial. : Journal of ovarian research.

Chicago

Engmann L L, Maslow B S, Kaye L A, Griffin D W, DiLuigi A J, Schmidt D W, Grow D R, Nulsen J C and Benadiva C A. 20190215. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial. : Journal of ovarian research.

Harvard

Engmann L. L., Maslow B. S., Kaye L. A., Griffin D. W., DiLuigi A. J., Schmidt D. W., Grow D. R., Nulsen J. C. and Benadiva C. A. (20190215). Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial. : Journal of ovarian research.

MLA

Engmann L L, Maslow B S, Kaye L A, Griffin D W, DiLuigi A J, Schmidt D W, Grow D R, Nulsen J C and Benadiva C A. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial. : Journal of ovarian research. 20190215.